

## Patritumab deruxtecan

## Chemical Properties

CAS No. :	2227102-46-5
Formula:	
Molecular Weight:	155.2 kDa
Storage:	Store at low temperature -20°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>

## Biological Description

Description	Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).
Targets(IC50)	Antibody-Drug Conjugates (ADCs)
In vitro	Patritumab deruxtecan is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody (patritumab) directed against HER3 covalently linked to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Upon binding to HER3, HER3-DXd translocates to lysosomes, where the linker is cleaved by lysosomal enzymes that are upregulated in tumor cells. The cytotoxic payload is then free to enter the nucleus, leading to cell death and, because the payload is membrane permeable, has potential bystander antitumor effects. [1]

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.0064 mL	0.0322 mL	0.0644 mL
5 mM	0.0013 mL	0.0064 mL	0.0129 mL
10 mM	0.0006 mL	0.0032 mL	0.0064 mL
50 mM	0.0001 mL	0.0006 mL	0.0013 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481